- Home
- IMA vs QNCX Comparison
IMA vs QNCX Comparison
Compare IMA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMA
- QNCX
- Stock Information
- Founded
- IMA 2019
- QNCX 2012
- Country
- IMA United States
- QNCX United States
- Employees
- IMA N/A
- QNCX N/A
- Industry
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMA Health Care
- QNCX Health Care
- Exchange
- IMA Nasdaq
- QNCX Nasdaq
- Market Cap
- IMA 92.2M
- QNCX 100.4M
- IPO Year
- IMA N/A
- QNCX 2019
- Fundamental
- Price
- IMA $8.11
- QNCX $1.77
- Analyst Decision
- IMA Buy
- QNCX Strong Buy
- Analyst Count
- IMA 1
- QNCX 6
- Target Price
- IMA $30.00
- QNCX $8.00
- AVG Volume (30 Days)
- IMA 91.8K
- QNCX 433.6K
- Earning Date
- IMA 11-15-2025
- QNCX 11-12-2025
- Dividend Yield
- IMA N/A
- QNCX N/A
- EPS Growth
- IMA N/A
- QNCX N/A
- EPS
- IMA N/A
- QNCX N/A
- Revenue
- IMA $4,300,000.00
- QNCX N/A
- Revenue This Year
- IMA N/A
- QNCX N/A
- Revenue Next Year
- IMA N/A
- QNCX N/A
- P/E Ratio
- IMA N/A
- QNCX N/A
- Revenue Growth
- IMA N/A
- QNCX N/A
- 52 Week Low
- IMA $7.24
- QNCX $0.72
- 52 Week High
- IMA $23.28
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- IMA N/A
- QNCX 49.65
- Support Level
- IMA N/A
- QNCX $1.76
- Resistance Level
- IMA N/A
- QNCX $1.95
- Average True Range (ATR)
- IMA 0.00
- QNCX 0.17
- MACD
- IMA 0.00
- QNCX -0.02
- Stochastic Oscillator
- IMA 0.00
- QNCX 27.62
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.